{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:40:26Z","timestamp":1781700026318,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.intimp.2019.106005","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T17:37:53Z","timestamp":1575308273000},"page":"106005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra\u00ae) dosing in patients with primary immunodeficiency"],"prefix":"10.1016","volume":"81","author":[{"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Baheti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Chapdelaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Rojavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tortorici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.intimp.2019.106005_b0005","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s10875-011-9557-z","article-title":"Efficacy and safety of Hizentra\u00ae, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency","volume":"31","author":"Borte","year":"2011","journal-title":"J. Clin. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2019.106005_b0010","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2019.106005_b0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.iac.2008.01.008","article-title":"Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol. Allergy Clin. North Am."},{"issue":"2","key":"10.1016\/j.intimp.2019.106005_b0020","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/cei.12485","article-title":"Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease","volume":"179","author":"Jolles","year":"2015","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2019.106005_b0025","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/11587030-000000000-00000","article-title":"Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency","volume":"50","author":"Wasserman","year":"2011","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.intimp.2019.106005_b0030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2249.2011.04376.x","article-title":"Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies","volume":"164","author":"Borte","year":"2011","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2019.106005_b0035","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/01.all.0000246619.49494.41","article-title":"Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies","volume":"6","author":"Gardulf","year":"2006","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2019.106005_b0040","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clim.2011.06.002","article-title":"Efficacy and safety of Hizentra\u00ae in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy","volume":"141","author":"Jolles","year":"2011","journal-title":"Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2019.106005_b0045","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10875-016-0243-z","article-title":"Quantitative Evidence of wear-off effect at the end of the intravenous IgG (IVIG) Dosing cycle in primary immunodeficiency","volume":"36","author":"Rojavin","year":"2016","journal-title":"J. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2019.106005_b0050","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/cei.12623","article-title":"Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency","volume":"181","author":"Niebur","year":"2015","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2019.106005_b0055","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2019.106005_b0060","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s10875-010-9423-4","article-title":"Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency","volume":"30","author":"Hagan","year":"2010","journal-title":"J. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2019.106005_b0065","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10875-009-9352-2","article-title":"Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis","volume":"30","author":"Shapiro","year":"2010","journal-title":"J. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2019.106005_b0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1006\/clim.2002.5215","article-title":"Express subcutaneous IgG infusions: decreased time of delivery with maintained safety","volume":"104","author":"Hansen","year":"2002","journal-title":"Clin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2019.106005_b0075","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/08830185.2012.732631","article-title":"Subcutaneous immunoglobulins: product characteristics and their role in primary immunodeficiency disease","volume":"31","author":"Melamed","year":"2012","journal-title":"Int. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2019.106005_b0080","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","article-title":"Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes","volume":"28","author":"Bonilla","year":"2008","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"10.1016\/j.intimp.2019.106005_b0085","doi-asserted-by":"crossref","unstructured":"M. Rojavin et al., Pharmacokinetic analysis of weekly vs biweekly IgPro20 dosing in patients with primary immunodeficiency, Clin. Pharmacol. Drug Develop., 2019 (in press).","DOI":"10.1002\/cpdd.753"},{"key":"10.1016\/j.intimp.2019.106005_b0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s13554-014-0018-0","article-title":"Enhancing patient flexibility of subcutaneous immunoglobulin G dosing: pharmacokinetic outcomes of various maintenance and loading regimens in the treatment of primary immunodeficiency","volume":"4","author":"Sidhu","year":"2014","journal-title":"Biol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2019.106005_b0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3810\/pgm.2013.11.2712","article-title":"Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency","volume":"125","author":"Landersdorfer","year":"2013","journal-title":"Postgrad. Med."},{"issue":"2","key":"10.1016\/j.intimp.2019.106005_b0100","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2249.2008.03620.x","article-title":"Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies","volume":"152","author":"Gustafson","year":"2008","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2019.106005_b0105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/11587030-000000000-00000","article-title":"Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency","volume":"50","author":"Wasserman","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.intimp.2019.106005_b0110","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.intimp.2019.03.034","article-title":"Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases","volume":"71","author":"Dumas","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2019.106005_b0115","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2147\/PPA.S60771","article-title":"Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment","volume":"8","author":"Espanol","year":"2014","journal-title":"Patient Prefer Adherence"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919315929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919315929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:16:56Z","timestamp":1761585416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919315929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":23,"alternative-id":["S1567576919315929"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.106005","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra\u00ae) dosing in patients with primary immunodeficiency","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.106005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106005"}}